Pulse Biosciences, Inc. (PLSE) Misses Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Pulse Biosciences, Inc. (PLSE) Misses Q3 EPS by 7c

Pulse Biosciences Reports Third Quarter 2020 Financial Results

November 9, 2020 4:05 PM EST

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation (NPS) technology, today announced financial results for the third quarter ended September 30, 2020.

Recent Highlights

Submitted a 510(k) Premarket Notification application to the U.S. Food and Drug Administration (FDA) for the CellFX® System seeking to obtain initial clearance for a general dermatologic indication. Potential clearance remains on track to be received as early as the first quarter of 2021. Received FDA Investigational Device Exemption (IDE) approval and... More